Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Army
Queensland Health
Moodys
Teva
Johnson and Johnson
Fuji
Federal Trade Commission
Fish and Richardson

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022505

« Back to Dashboard

NDA 022505 describes EGRIFTA, which is a drug marketed by Theratechnologies and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the EGRIFTA profile page.

The generic ingredient in EGRIFTA is tesamorelin acetate. Two suppliers are listed for this compound. Additional details are available on the tesamorelin acetate profile page.
Summary for 022505
Tradename:EGRIFTA
Applicant:Theratechnologies
Ingredient:tesamorelin acetate
Patents:3
Suppliers and Packaging for NDA: 022505
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505 NDA EMD Serono, Inc. 44087-2011 E 44087-2011-2
EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505 NDA Theratechnologies Inc. 62064-011 N 62064-011-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrengthEQ 1MG BASE/VIAL
Approval Date:Nov 10, 2010TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 26, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
Patent:➤ Sign UpPatent Expiration:Jul 14, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
Patent:➤ Sign UpPatent Expiration:Aug 14, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

Expired US Patents for NDA 022505

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
Fish and Richardson
QuintilesIMS
Boehringer Ingelheim
Queensland Health
Accenture
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.